Advancing ODT Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Advancing ODT Technology
Orally disintegrating tablets (ODTs) continue to attract attention as an alternative to conventional oral dosage forms.


Pharmaceutical Technology



Patricia Van Arnum
Offering ease of use, the potential for increased patient compliance, and a way to extend the product life cycle of a drug, orally disintegrating tablets (ODTs) continue to make inroads into the market for solid-dosage forms.

Definition of ODT

Generally, an ODT is a solid-dosage form that disintegrates and dissolves in the mouth (either on or beneath the tongue or in the buccal cavity) without water within 60 seconds or less (1). The US Food and Drug Administration's Center for Drug Evaluation and Research developed the following definition for an ODT as a new dosage form in 1998: "A solid dosage form containing medicinal substances, which disintegrates rapidly, usually within a matter of seconds, when placed upon the tongue" (2).

Earlier this year, FDA issued a draft guidance, Guidance for Industry: Orally Disintegrating Tablets (2), to recommend that, in addition to the original definition, ODTs be considered solid oral preparations that disintegrate rapidly in the oral cavity with an in vitro disintegration time of approximately 30 s or less, when based on the United States Pharmacopeia disintegration test method or alternative (see sidebar, "FDA issues ODT draft guidance").

Market potential


Table I. Select examples of commercialized orally disintegrating tablets.
The global ODT market (based on ex-factory sales to wholesalers) was estimated at $2.4 billion in 2004 and $3 billion in 2006, according to Technology Catalysts International (3). Table I lists select examples of ODT drugs that are commercialized on the US market.

Recent market studies indicate that more than half of the patient population prefers ODTs to other dosage forms, and most consumers would ask their doctors for ODTs (70%), purchase ODTs (70%), or prefer ODTs to regular tablets or liquids (greater than 80%) (1).

Mechanism of ODT drugs

Generally, ODTs are formulated to disperse rapidly in the mouth, enabling medication to be swallowed without water, thereby increasing convenience and compliance across a broad range of indications and patient types, including the young, elderly, and active patients, explains Susan Banbury, project manager with Catalent Pharma Solutions (Swindon, UK). Following dispersion, the formulations are typically swallowed, and the drug is absorbed in the same way as conventional solid-oral dosage forms.

"However, ODTs may also be used to deliver drugs to the oral cavity, for local action or, in some cases, absorption across the oral mucosa, thereby avoiding first-pass hepatic metabolism and potentially increasing the rate and extent of uptake, and reducing undesirable metabolites," says Banbury (4). The potential for such pregastric absorption rests largely in the physicochemical characteristics of the drug molecule. The intrinsic taste of the drug is also a significant consideration for all ODT formulations.

Types of ODTs


FDA issues draft ODT guidance
For ease of comparison, ODTs may be categorized into two main groups: lyophilized formulations and loosely compressed tablets. Thin-film strips form a third category of solid, unit-dose, orally disintegrating products that aim to meet the same objectives of ease of administration, patient convenience, and improved compliance.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: Pharmaceutical Technology,
Click here